Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
liver neoplasms/tyrosine
Link salvestatakse lõikelauale
Leht 1 alates 16 tulemused
Itacitinib in Advanced Hepatocellular Carcinoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
JAKaL is a single arm phase Ib study evaluating the effect of Itacitinib in 25 patients with advanced HCC.
Many patients diagnosed with HCC will have advanced disease where only palliative care is offered to them, this could account for the relatively low reported 5-year survival rate of
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The study has three main parts:
Screening: Participants will have test, procedures, and assessments done for safety and eligibility. Some may be done for research purposes only. Several visits may be needed to complete the screening part of the study.
Study Drug Period: During this part,
The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Primary liver cancer is a common malignant tumor in the world. Its pathogenesis is concealed and clinically asymptomatic. It is mostly in the middle and late stages of the disease. It is often combined with different degrees of cirrhosis. The liver function reserve is poor.About 80% of patients are
Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Ovarian cancer and fallopian tube cancer are common gynecological malignancies in our country. Ovarian cancer ranks the second in the incidence of gynecologic malignancies. The mortality rate is the highest. The following three major characteristics exist: First, 70% of the patients are advanced
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Hereditary Tyrosinemia type 1 (HT-1) is a rare genetic disorder in which the newborn child lacks the ability to break down the amino acid tyrosine. As a result of this deficiency, toxic sub-stances build up in the blood and can cause liver failure, kidney dysfunction and neurological problems. There
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Sorafenib is multiple tyrosine kinase inhibitor. It blocks path that such as Raf-1, Vascular Endothelial Growth Factor Receptor (VEGFR), Platelet-Drived Growth Factor Receptor-β (PDGFR-β), c-Jit, Flt-3. Sorafenib was known to increase life rate about processed hepatocellular carcinoma. So it is
TACE Combined With Iodine-125 Seeds Implantation for HCC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background and purpose:
Hepatocellular carcinoma (HCC) is the 5th most common cancer in the world and the 3rd most prevalent cause of tumor-related deaths. Portal vein tumor thrombus (PVTT) occurs in up to 44% of HCC patients at the time of death and approximately 10-40% of patients at time of
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Apatinib is a VEGFR targeting tyrosine kinase inhibitor, which has preliminary demonstrated the efficacy and safety in treatment of advanced hepatocellular carcinoma by phase II stage research. Pulmonary metastasis of hepatocellular cancer is one of the difficulties in clinical practice,because it's
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Introduction Hepatocellular carcinoma (HCC) is a major health problem, accounting for more than 626,000 new cases per year worldwide. It is the third highest cause of cancer-related death globally. In the west, the disease is diagnosed in 30 to 40% of all patients at early stages and is amenable to
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and much more common in male than in female. Each year, the number of patients with HCC in China alone contributes to about 50% of the total cases and deaths in the world. In men, poor prognosis makes HCC the second most
Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Numerous chemotherapeutic regimens have been tested for use against hepatocellular carcinoma (HCC). HCC is, however, highly resistant to chemotherapy; doxorubicin and 5- fluorouracil containing regimens, alone or in combinations, results in less than a 20% response, with a median survival of less
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
